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INTRODUCTION
Neglected tropical diseases (NTDs) are a diverse group of 20 communicable diseases that prevail in
149 tropical and subtropical countries (1) (Table 1). They are identified as “neglected” because they
persist predominantly in the poorest and the most marginalized populations living without
adequate sanitation and in close contact with infectious vectors and domestic animals and
livestock. NTDs are also neglected in terms of investment in R&D to the extent provided to
HIV, malaria and TB. Over one billion people from the world’s most disadvantaged and poorest
communities suffer from at least one NTD, which can significantly impact upon their physical and
mental health. NTDs are markers, agents and drivers of poverty (2).A NEW NTD ROAD MAP
The launch of Frontiers in Tropical Diseases coincides with the official launch in January 2021 of a
new road map for Neglected Tropical Diseases (NTDs) for 2021−2030 - Ending the neglect to attain
the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 (3). The
new roadmap replaces the previous roadmap launched in 2012, which in spite of the substantial
progress made across several NTDs, suffered from being over ambitious with many targets
unfulfilled by 2020. Thankfully the new roadmap is greatly improved with more detail and
finesse generated by broader engagement and consultation with NTD stakeholders, national
programme managers and academia. It reflects and is framed by the growing commitment to
achieving sustainable development goals (SDGs) and universal health coverage. It acknowledges
how fragile and vulnerable programmes are to political instability, conflict, migration, climate
change, epidemics/pandemics and anti-microbial resistance as barriers to achieving the goals laid
out in the roadmap.
The new road map seeks to promote a paradigm shift in the way NTDs are addressed by;
1) moving away from process driven targets to measures of the impact on public health, 2) replacing
vertical and siloed disease specific programmes with holistic cross-cutting approaches integrated
into national health systems with a people and community centred focus, and 3) to transferersin.org March 2021 | Volume 2 | Article 6697261
Taylor Research and Innovation for NTDsprogramme ownership away from partner support and reliance
on donor funding to country ownership with NTDs integrated
into national health plans and budgets.
The overarching goals for 2021-2030 decade are:
• To reduce by 90% the number of people requiring treatment
for NTDs
• To eliminate at least one NTD in 100 countries
• To eradicate two diseases (dracunculiasis and yaws)
• To reduce by 75% the disability-adjusted life years (DALYs)
related to NTDs
Most importantly, from the perspective of a new academic
journal the new roadmap fully embraces the need for “research
and innovation as fundamental enablers for programmatic
progress for all NTDs”. It includes summaries of the gaps in the
tools and processes required for each of the 20 diseases with a
“traffic light” coded table, which includes a realistic
representation of amber and red requirements highlighting the
broad range of research and innovation needed to achieve
these goals.NTD RESEARCH AND INNOVATION
There are many new examples of where innovative scientific
approaches are providing new and more effective tools and
understanding to improve and strengthen existing strategies.
After being previously excluded from many programmatic
approaches, vector control tools are re-emerging to add novel
approaches to NTD control. Examples include the introduction
ofWolbachia infected Aedes aegypti, which render the mosquitos
refractory to arboviral transmission leading to a 77% reduction
in dengue incidence in community trials in Indonesia carried out
under the umbrella of the “World Mosquito Programme” (4).
Another example is the deployment of vector control as an
adjunct strategy to case detection and treatment for the control
of Gambian human African trypanosomiasis thanks to the
development of “Tiny Targets” - cost-effective traps for the
tsetse fly vector (5).
Another remarkable success story is the Guinea Worm
Eradication Programme. Even without any drug, vaccine or
diagnostic, highly effective public health measures including
access to safe drinking water, education, surveillance and
copepod control has led to the incidence of human
Dracunculus medinensis declining from 3.6 million cases in theFrontiers in Tropical Diseases | www.frontiersin.org 21980’s to 53 cases in 2019 (6). One of only two NTDs targeted for
eradication, the programme has encountered an entirely
unexpected challenge in the “last mile”. The parasite so
frustratingly close to being eradicated from humans appears to
have expanded into zoonotic animal reservoirs including, dogs,
cats and baboons, with genomic analysis supporting a common
origin of animal and human parasite populations (7). This
together with the extreme challenges of surveillance in
countries blighted by civil unrest and insecurity and the strict
criteria for eradication demanded by the International
Commission for the Certification of Dracunculus Eradication,
questions whether Guinea worm eradication is still achievable
and further re-enforces the need for research and innovation
right up until the end.
The expansion of the guinea worm life-cycle to include
zoonotic hosts re-enforces the concept of multi-sectorial
engagement to bring the relevant expertise in to meet the
challenges that NTD diseases face. Schistosomiasis is another
example where hybridisation between human and cattle parasites
has radically changed the traditional view of the parasites
epidemiology, with a fundamental impact on the effectiveness
of current strategies used to control urogenital schistosomiasis
(8). Hybridization within and between species can accelerate
parasite evolution, expand host-range, increase transmission and
virulence potential and alter responsiveness to drug treatment
(9) – all of which could impact on the NTD roadmap targets for
existing control and elimination strategies.LEAVE NO ONE BEHIND
NTDs are stigmatized, can be disabling and often inhibit
individuals from being or feeling able to care for themselves or
their families - all of which promote poverty on a global scale
(10). Individuals living in remote areas with limited access to
effective health care are most vulnerable to NTDs and their
consequences, such as malnutrition, anaemia, serious or
permanent morbidity and associated disability, illness and
death. New research approaches applied to NTDs have
uncovered the significant mental health impact these diseases
can inflict. The use of narrative and intersectional analysis by Dr.
Laura Dean (11) and her team illustrates the terrible
consequences of onchocerciasis on people that, for one reason
or another, have been excluded from the control programme,
leading to ostracization and suicidal thoughts due to theirTABLE 1 | The Neglected Tropical Diseases.
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Human African trypanosomiasis (sleeping
sickness)
Onchocerciasis (river blindness) Snakebite envenoming
Dengue Leishmaniasis Rabies Taeniasis and cysticercosis
Dracunculiasis (Guinea worm) Leprosy Scabies and other ectoparasitoses Trachoma
Echinococcosis Lymphatic filariasis Schistosomiasis Yaws (endemic
treponematoses)March 2021 | Volume 2 | Article 669726
1Written informed consent was obtained from the participants and the name
used are pseudonyms (11).
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These people have been “left behind” to face the traumatic and
devastating impact of these diseases alone. This work has
emphasised how important it is for NTD programmes to
address the psychosocial distress and mental health conditions
(such as depression or anxiety) that these people and their
families face, which should now be embedded in the strategies
of NTD programme implementors (12).NEGLECTED NEEDS
Some areas of research that are embedded in all other infectious
disease fields have traditionally been neglected by the NTD
community. One example being the development of resistance
to NTD drugs, which many programmes are exclusively reliant
upon. In contrast to insecticides, malaria, HIV, TB, anti-
microbial resistance and veterinary anti-parasitic drugs, where
resistance management is integrated into their respective
treatment strategies - resistance to NTD drugs is rarely
acknowledged as a risk. There is currently no systematic
screening or monitoring and evaluation for resistance
development in NTD programmes. This is all the more
remarkable considering many of the mass-drug administration
approaches, several of which rely on a single drug, are likely to
promote resistance. The NTD community needs to embrace the
concept urgently and accept that any organism placed under
selective pressure will evolve. Thankfully a number of academic
consortia, such as the Consortium for Anthelminthic Resistance
and Susceptibility (13) and Starworms (Stop Anthelmintic
Resistant Worms) (14) are turning their attention to this
neglected need, which will hopefully lead to resistance
management being incorporated into programme strategies, to
protect the legacy of existing NTD drugs and promote the
translation of new drugs, where needed.
Another neglected need is in NTD diagnostics, a critical gap
identified by the new roadmap (3). Diagnostics have received
poor investment and prioritisation within NTD programmatic
planning, which compromise the ability to monitor and evaluate
programme progress, validation of programmatic endpoints,
resistance management, surveillance and impact on health. Of
the four priorities areas identified in the roadmap (diagnostics,
monitoring and evaluation, access and logistics, advocacy and
funding), diagnostics is the area in most need of research and
innovation with 18 (out of 20) NTDs listing diagnostics as
requiring critical action to meet the 2030 targets (3). In anBOX 1 | Jon and Hannah’s story of suffering from onchocerciasis1.
Jon’s story (abridged):
Jon is a 46 years old school-teacher from Liberia. He established a school in
his community during Liberia’s conflict to educate children in his community in
the absence of government schools at the time. Jon kept a diary of his
experience of suffering from onchocerciasis on his wall in chalk.
• In 1985 he first experienced severe itching and was treated with
Banocide (diethylcarbamazine) at the local hospital
• In 1990, the itching returned, but during the conflict accessing medicine
was difficult
• In 2005 Jon sought help for his illness - his first trip to the hospital failed
to provide any help
• He next accessed traditional medicine to manage the itching
• In 2012 he visited a larger hospital and was mis-diagnosed with
glaucoma and cataract and given medication to reduce his blood
pressure. The itching continued.
• When the Mectizan donation programme visited his community he was
wrongly charged for the medicine
• By now his vision was becoming impaired and he found it difficult to read
his diary on the wall
• “I feel hurt when I open it (his eyes). I can see no writing. Hmm I can see
no writing”
• Since this last entry to his diary on the wall Jon’s wife left and took his
children to another community
• He can no longer fix his leaking roof and often sleeps on wet ground and
faces difficulty finding food
• “I just sit down the whole day. You alone and you know what it means”
Jon described his last chalk marking and going blind as the end of his
journey as he now felt isolated and alone. Jon no longer teaches in the school,
which he acknowledges affects him and the community. As we move toward
onchocerciasis elimination in many contexts, it is vital that people like Jon are not
left behind and that this isn’t the end of their story.
Hannah’s story (abridged):
In 1989, Hannah was successful at school and had ambitions to be a
doctor. In 1991, as a teenager, she experienced severe itching and her eyes
watered in direct light.
• Due to the ongoing conflict in Liberia her mother sought health care in
Guinea and the Ivory Coast (Cote d’Ivoire) from traditional medicine.
• Returning to Liberia health care from the hospital was too expensive
• In 1994, Hannah woke to find she could no longer see her parents
• “I can’t see, I can’t see, [I] was looking all around for things from beside
[me], [I] was looking for something to just finish [my] life.”
• Since 1994 Hannah described how “men will come and tell me they will
help me, but after a period of time, they leave”
• Hannah gave birth to four children but had to send them to her sister as
she and her mother struggle for food
• Hannah’s mother has become her primary carer, which led Hannah to
feel a liability to her mother “who will take care of me when my mother
dies”
• Hannah struggles to access sanitation and clean water due to her
blindness
• Hannah’s mother had to give up farm work and her job as a traditional
mid-wife to care for her daughter
• Her mother was unable to go to church “[I] can’t go there [to church] to
leave her… [I] can’t go nowhere to leave her...for that reason she just
decided to be glue to her.”
• When asked why, she explained “because Hannah always saying she
will kill herself. So, [I am] afraid maybe if [I] go out, she may come and
take something to harm herself. So, for that reason [I] don’t want to go
far from her.”
• Hannah and her mother struggle for food and rely on donations from
people in their communityHannah’s story highlights the impact that disability caused by
onchocerciasis can have on an individual, but also on other members of the
household. The impact on Hannah, her mother and children, presents a need forholistic support interventions for people who are living with the clinical
manifestations of onchocerciasis, such as skin disease and blindness, to
ensure their psychological, social and physical support needs are met. It is
only if these things are provided that we will ensure that no-one is left behind in
managing the impacts of onchocerciasis.March 2021 | Volume 2 | Article 66972s
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Diagnostic Technical Advisory Group (DTAG) (15). In the face
of limited resources one of the first tasks was to prioritize the
NTDs most in need of diagnostic development, which brought
the list down to 14 from the 18 listed in the roadmap (15). The
establishment of the DTAG is a welcome first step to raise the
profile and coordinate the NTD communities approaches and
activities to overcome the challenges of NTD diagnostic
development. However, without concerted lobbying and
advocacy to turn around the lack of investment and funding to
discover, develop and translate new diagnostic tools these
challenges will continue to threaten the ability to meet the
2030 targets across the majority of NTDs.TRANSLATION OF RESEARCH
AND INNOVATION
Translating the outputs of NTD research discovery and
development remains a barrier to the timely testing and
implementation of new products and approaches. A
disproportionately low level of investment in funding for
translational research and access to the regulatory expertise for
product development further impact on translational research
progress. Product Development Partnerships have been
established with a focus on NTDs including DNDi2, FIND3
and funders with dedicated NTD investment portfolios





Frontiers in Tropical Diseases | www.frontiersin.org 4among others. DNDi and FIND have been successful in meeting
their targets, with new treatments for human African
trypanosomiasis (HAT), visceral leishmaniasis and Chagas
disease and new diagnostics for HAT and other kinetoplastids
(16). Much of the early success came from “low-hanging fruit”
from re-purposed drugs and combinations (17), but the current
capacity of product portfolios, pipelines, timeframes and a
restricted focus on selected NTDs2–5, falls well short of the gap
needs analysis included in the NTD road map. Increased capacity
and a broader diversity will be required to meet the translational
requirements for the roadmap targets to be achieved.CONCLUSION
This Speciality Grand Challenge is a personal perspective of a few
of the key challenges faced by the NTD community and some
examples of how the academic NTD community have responded
with innovation and research to address these challenges. There
are plenty of other challenges, many of which are highlighted in
the needs gap analysis in the new NTD roadmap - and others will
arise as we travel toward these targets and goals. The aim of the
NTD section of Frontiers in Tropical Diseases is to provide an
academic forum for the critical evaluation and promotion of
research and innovation as fundamental enablers for
programmatic progress for all Neglected Tropical Diseases.AUTHOR CONTRIBUTIONS
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